Imagine a mosquito-borne（忍受，负荷） virus that has already infected millions of people in recent outbreaks in South and Southeast Asia, the islands of the Indian Ocean, Africa and northern Italy. Although seldom fatal（致命的，毁灭性的） , it causes highly painful arthritis¹（关节炎） -like symptoms that can linger（消磨，磨蹭） for months or even years. It's capable of adapting to spread through a mosquito species common in much of North America. And no vaccine² or treatment exists to protect humans from its effects. The scenario³ may sound like something dreamed up as a training exercise by public health authorities, but the virus is all too real. Called chikungunya（基孔肯亚病） , from an East African tribal⁴ word describing the contorted（歪曲的，扭曲的） postures⁵ of its pain-wracked victims, the pathogen has been the focus of intense scientific interest ever since a 2006 outbreak on the island of La Reunion in the Indian Ocean infected about 266,000 people, killing⁶ 260 of them.

Now, researchers at the National Institute of Allergy⁷ and Infectious Diseases, the University of Texas Medical Branch at Galveston, Purdue University and Bioqual Inc. have developed an experimental vaccine for chikungunya virus and successfully tested it in monkeys. Described in a paper appearing in the March issue of Nature Medicine, the vaccine is composed of noninfectious（非传染性的） "virus-like particles." Although coated with the same proteins that enable chikungunya to pass through cell membranes⁸（细胞膜） , the vaccine particles lack the proteins that chikungunya uses to replicate⁹ inside cells. They look like chikungunya to the immune systems of rhesus（恒河猴） macaques（猕猴） , however, which respond to exposure by generating antibodies that defend the monkeys from infection by the real virus.

"This vaccine did an excellent job of protecting the macaques from chikungunya," said UTMB professor Stephen Higgs, one of the paper's authors. "That it worked so well in a primate¹⁰（灵长目动物的） model is good news — these macaques are quite similar to humans in their response to chikungunya, and we badly need to develop an effective human vaccine for this virus."

To create the virus-like particles used in the experimental vaccine, the researchers used genetic¹¹ engineering techniques to produce the structural¹² proteins that produce the spiky¹³（尖刻的，易怒的） , roughly spherical¹⁴（球形的） exterior¹⁵ possessed¹⁶ by chikungunya viruses before they have entered a cell. The proteins then assembled themselves into harmless balls that resembled particles of Sindbis virus — a relative of chikungunya and a fellow member of the alphavirus（甲病毒） genus, which also includes a number of insect-borne viruses capable of causing dangerous encephalitis（脑炎） in humans.

Serum¹⁷（血清） drawn¹⁸ from rhesus macaques injected with the virus-like particles contained substantial levels of antibodies that inactivated¹⁹ chikungunya virus. Two groups of macaques were then inoculated²⁰（接种，注射） , either with virus-like particles or with a sham²¹（虚假的） solution containing no vaccine. When the researchers challenged the monkeys by injection with chikungunya 15 weeks later, they found that the vaccine had completely protected the animals from the virus.

Dr.Gary Nabel, director of the NIAID's Vaccine Research Center and corresponding author on the Nature Medicine paper, said that the vaccine's effectiveness against chikungunya had led his group to plan follow-up investigations²² into whether the same approach would work against other alphaviruses, such as Western and Eastern equine encephalitis viruses（马脑脊髓炎病毒） (both responsible for periodic outbreaks in the United States), and Africa's o'nyong-nyong virus.